Infusion of allogeneic umbilical cord blood hematopoietic stem cells in patients with chemotherapy‑related myelosuppression

Yeshurun M, Labopin M, Blaise D, et al: Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer. 120:885–863. 2014.

Dale DC, McCarter GC, Crawford J and Lyman GH: Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw. 1:440–454. 2003.PubMed/NCBI

Zhong XY, Zhang B, Asadollahi R, et al: Umbilical cord blood stem cells: what to expect. Ann NY Acad Sci. 1205:17–22. 2010. View Article : Google Scholar : PubMed/NCBI

Wagner JE and Gluckman E: Umbilical cord blood transplantation: the first 20 years. Semin Hematol. 47:3–12. 2010.PubMed/NCBI

Sun HP, Zhang X, Chen XH, et al: Human umbilical cord blood-derived stromal cells are superior to human umbilical cord blood-derived mesenchymal stem cells in inducing myeloid lineage differentiation in vitro. Stem Cells Dev. 21:1429–1440. 2012. View Article : Google Scholar : PubMed/NCBI

Yang WZ, Zhang Y, Wu F, et al: Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions. J Transl Med. 8:752010. View Article : Google Scholar : PubMed/NCBI

Zhang XZ, Xu YL and Tian R: The research and application of cord blood plasma. Lin Chuang Xue Ye Xue Za Zhi. 1:39–40. 2003.(In Chinese).

Liao C, Liu B and Huang Y: Establishment of cord blood stem cell bank and its clinical application. Zhonghua Xue Ye Xue Za Zhi. 22:411–414. 2001.(In Chinese).

Isasi R, Dalpe G and Knoppers BM: Fostering public cord blood banking and research in Canada. Stem Cells Dev. 22(Suppl 1): 29–34. 2013. View Article : Google Scholar : PubMed/NCBI

Wang BH, Zhang MZ, Fu XR, et al: Pathogenesis, prevention and treatment of chemotherapy and radiotherapy induced myelosuppression: the state of the art. Zhong Liu Ji Chu Yu Lin Chuang Za Zhi. 26:162–165. 2013.(In Chinese).

Duong CD and Loh JY: Laboratory monitoring in oncology. J Oncol Pharm Pract. 12:223–236. 2006. View Article : Google Scholar : PubMed/NCBI

Lv M and Huang XJ: Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go. J Hematol Oncol. 5:102012. View Article : Google Scholar : PubMed/NCBI

Riordan NH, Chan K, Marleau AM and Ichim TE: Cord blood in regenerative medicine: do we need immune suppression. J Transl Med. 5:82007. View Article : Google Scholar : PubMed/NCBI

Jiang XF, Wang GZ, Li GX, et al: Transplantation of unrelated donor umbilical cord blood in 28 patients with malignant hematopathy. Zhonghua Xue Ye Xue Za Zhi. 27:279–280. 2006.(In Chinese).

Gu DS, Liu B and Han ZC: The research and application of cord blood stem cells. Zhongguo Ke Xue Yuan Sheng Wu Ke Xue Yu Ji Shu Ju. 18:323–327. 2006.(In Chinese).

Wang XH, Zhang XZ, Shi HZ, et al: The evaluation of Epo, G-CSF, IL-2, IL-6 in cord blood plasma. Zhonghua Xue Ye Xue Za Zhi. 11:391999.(In Chinese).

Biesecker LG and Emerson SG: Interleukin-6 is a component of human umbilical cord serum and stimulates hematopoiesis in embryonic stem cells in vitro. Exp Hematol. 21:774–778. 1993.PubMed/NCBI

Sanders M, Sorba S and Dainiak N: Insulin-like growth factors stimulate erythropoiesis in serum-substituted umbilical cord blood cultures. Exp Hematol. 21:25–30. 1993.PubMed/NCBI

Carow CE, Hangoc G and Broxmeyer HE: Human multipotential progenitor cells (CFU-GEMM) have extensive replating capacity for secondary CFU-GEMM: an effect enhanced by cord blood plasma. Blood. 81:942–949. 1993.

An YH, Zhou RX, Zhang GJ, et al: Transplantation of cord blood hematopoietic stem cells: effects on marrow function of cancer patients on chemotherapy. Qingdao Da Xue Yi Xue Yuan Xue Bao. 36:88–90. 2000.(In Chinese).